CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-18

Study Completion Date

2025-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine which standard of care strategy will best benefit very severe Acute Exacerbation (AE) of Chronic Obstructive Pulmonary Disease (COPD), single versus reinforced with ECCO2R and assess the respective efficacy and the safety. Very severe AE of COPD will be defined by high risk of Non-Invasive Ventilation (NIV) failure defined by need of intubation and/or in-Intensive Care Unit (ICU) mortality (Stratum 1) or by Invasive Mechanical Ventilation (IMV) after NIV failure and/or with severe hyperinflation and hypercapnia (Stratum 2).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of FeNO During and Following Acute COPD Exacerbation

NCT01761006

Chronic Obstructive Pulmonary Disease

TERMINATED

Effects of SIMEOX on Flow and Volume in Healthy Subjects and Patients With COPD

NCT04150601

Healthy Pulmonary Disease, Chronic Obstructive

COMPLETED NA

Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State

NCT02103374

Severe Chronic Obstructive Pulmonary Disease

COMPLETED PHASE4

Exhale (R) Stent for Emphysema

NCT00207337

Emphysema

COMPLETED PHASE2/PHASE3

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After inclusions, all patients from Stratum 1 (at high risk of NIV failure) and Stratum 2 (Intubation-IMV) will be randomly assigned to the single standard of care treatment or to the strengthen standard treatment reinforced with ECCO2R . Weaning of IMV in the strengthen standard of care group will precede weaning of ECCO2R. Weaning of NIV in the strengthen standard of care group will precede weaning of ECCO2R, except for patients with long-term NIV. The patients will undergo a maximum of 33 visits over the 1-year study duration, split in 3 successive periods: selection period, treatment period (until the discharge of the ICU or day 28 after randomisation), follow-up period after the discharge of the ICU (or after day 28) up to 1 year (after randomisation).

Selection period: before randomisation, demographics, medical and surgical history, clinical examination (including physical examination, respiration rate, encephalopathy score, sedation score, pain assessment, Simplified Acute Physiology Score 2, central body temperature, systolic and diastolic blood pressures, heart rate), blood sampling, electrocardiogram and ventilator parameters will be recorded.

Follow-up period: ECCO2R will start as soon as possible after randomisation in patients allocated to the strengthen standard of care group. All patients will be evaluated 12 + 2 hours after randomisation, followed by a daily visit with the collection of the following data if applicable: clinical examination, ECCO2R parameters, ventilator parameters, concomitant medications (including sedative drugs), occurrence of adverse events, date, time and criteria if endotracheal intubation (stratum 1). Arterial blood gases, hematology and serum biochemistry parameters will be assayed daily.

End of Research period: all patients will be evaluated at day 60 (+ 7 days), Day 90 (+ 7 days), Day 180 (+ 7 days) and 1 year (+ 7 days) at least by phone contact, with collection of: vital status, functional status (Severely Disabled or not, Katz Index of Independence in Activities of Daily Living), date of ICU discharge (if \> Day 28), date of hospital discharge, occurrences of ICU re-admissions, of adverse events, type and length of mechanical ventilation needed if applicable.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Acute Exacerbation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, multi-centre, randomized, controlled, open-label

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single standard of care

COPD patients who require respiratory support for severe acute exacerbation (AE), either with NIV or with IMV.

Group Type NO_INTERVENTION

No interventions assigned to this group

Strengthen standard of care reinforced with ECCO2R

COPD patients who require respiratory support for severe acute exacerbations (AE), either with NIV or with IMV reinforced with ECCO2R

Group Type OTHER

ECCO2R

Intervention Type DEVICE

ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECCO2R

ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Known or suspected diagnosis of COPD based on clinical history, pulmonary function test when available, arterial blood gases, physical examination, and chest radiograph
* Worsening dyspnea for \< 2 weeks
* Written informed consent signed by patients or their surrogates, with possibility of an emergency procedure with deferred consent
* Patient affiliated to a Social Security System (excluding "AME: aide médicale d'état")
* Negative serum or urinary β-hCG for women of child-bearing potential
* Very severe AE criteria defined either by:

1. Stratum 1: high likelihood of NIV failure defined by PaCO2 \> 55 mmHg and pH \< 7.25, either at baseline and/or after at least one hour of NIV
2. Stratum 2: intubation and IMV since less than 72 hrs, either after NIV failure and/or with pH \< 7.30 and PaCO2 \> 55 mmHg and PEEPi (end-expiratory occlusion) \> 5 cmH2O, while on Assist-Controlled Ventilation with the following parameters: VT: 8 ml/kg, RR: 12/min., applied PEEP: 0 cmH2O

Exclusion Criteria

* Hemodynamic instability
* Known allergy to heparin or to any of the excipients of the specialty used
* Contra-indications to heparin listed in the SmPC of the specialty used.
* History of type II Heparin-induced thrombocytopenia
* Thrombocytopenia (platelets \< 100.000/mm3)
* Recent major surgery
* Haemorrhagic disorders such as:

* Organic lesion likely to bleed
* Bleeding manifestations or tendencies linked to disorders of hemostasis
* Intracerebral hemorrhage
* Uncontrolled arrhythmia
* Bleeding diathesis
* Body Mass Index \> 35 kg/m2
* PaO2/FiO2 \< 180 mmHg
* Do not intubate order
* Fibrosing idiopathic interstitial pneumonitis (based on the available medical files)
* Neuromuscular diseases (based on the available medical files)
* Patients with tracheotomy
* Patients with severe concomitant chronic systemic disease with a limited probability of survival (\< 6 months)
* Severely disabled (confinement to bed and inability to wash or dress alone) patients before AE
* Pregnant woman
* Participation in another interventional study involving human participants up to their ICU discharge, whether the studies include an investigational medical device, or being in the exclusion period at the end of a previous study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No